Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 2000 May; 82(10): 1636–1645.
Published online 2000 April 27. doi:  10.1054/bjoc.2000.1214
PMCID: PMC2374517

Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study

R Skinner,1 S J Cotterill,1 M C G Stevens,2 and on behalf of the Late Effects Group of the United Kingdom Children’s Cancer Study Group (UKCCSG)


The aim of this multicentre study was to document the nephrotoxicity associated with ifosfamide and evaluate risk factors in 148 children and young people with sarcomas who underwent investigation of renal function on one occasion each, at a median of 6 (range 1–47) months after completion of ifosfamide (median dose 62.0 (range 6.1–165.0) g/m2). Investigations included glomerular filtration rate (GFR), serum bicarbonate (HCO3) and phosphate (PO4), and renal tubular threshold for phosphate (Tmp/GFR). A clinically relevant ‘nephrotoxicity score’ was derived. GFR was < 90 ml/min/1.73 m2in 61 of 123 evaluable patients, Tmp/GFR < 0.9–1.1 mmol/l (age-dependent) in 45/103, serum PO4< 0.9–1.mmol/l (age-dependent) in 28/135, and serum HCO3< 20 (< 18 in infants) mmol/l in 22/95. Of 76 fully evaluable patients: 50% had mild, 20% moderate and 8% severe nephrotoxicity. Higher total ifosfamide dose correlated significantly with greater glomerular and tubular toxicity (P< 0.01); other risk factors, including age at treatment, demonstrated no consistent significant independent effect. Chronic ifosfamide-related glomerular and proximal tubular toxicity were common in this large comprehensive study. Restriction of total ifosfamide dose to < 84 g/m2will reduce the frequency of, but not abolish, clinically significant nephrotoxicity, whilst doses > 119 g/m2are associated with a very high risk of severe toxicity. © 2000 Cancer Research Campaign

Keywords: ifosfamide, nephrotoxicity, children, adolescents, cancer

Full Text

The Full Text of this article is available as a PDF (141K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Arndt C, Morgenstern B, Wilson D, Liedtke R, Miser J. Renal function in children and adolescents following 72 g/m2 of ifosfamide. Cancer Chemother Pharmacol. 1994;34(5):431–433. [PubMed]
  • Ashraf MS, Brady J, Breatnach F, Deasy PF, O'Meara A. Ifosfamide nephrotoxicity in paediatric cancer patients. Eur J Pediatr. 1994 Feb;153(2):90–94. [PubMed]
  • Ashraf MS, Skinner R, English MW, Craft AW, Pearson AD. Late reversibility of chronic ifosfamide-associated nephrotoxicity in a child. Med Pediatr Oncol. 1997 Jan;28(1):62–64. [PubMed]
  • Barratt TM, McLaine PN, Soothill JF. Albumin excretion as a measure of glomerular dysfunction in children. Arch Dis Child. 1970 Aug;45(242):496–501. [PMC free article] [PubMed]
  • Bleyer WA. The impact of childhood cancer on the United States and the world. CA Cancer J Clin. 1990 Nov-Dec;40(6):355–367. [PubMed]
  • Boddy AV, English M, Pearson AD, Idle JR, Skinner R. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. Eur J Cancer. 1996 Jun;32A(7):1179–1184. [PubMed]
  • Bremner DN, McCormick JS, Thomson JW. Clinical trial of isophosphamide (NSC-109724)--results and side effects. Cancer Chemother Rep. 1974 Nov-Dec;58(6):889–893. [PubMed]
  • Brodehl J, Gellissen K, Weber HP. Postnatal development of tubular phosphate reabsorption. Clin Nephrol. 1982 Apr;17(4):163–171. [PubMed]
  • Burk CD, Restaino I, Kaplan BS, Meadows AT. Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor. J Pediatr. 1990 Aug;117(2 Pt 1):331–335. [PubMed]
  • Caron HN, Abeling N, van Gennip A, de Kraker J, Voûte PA. Hyperaminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and platinate containing regimens. Med Pediatr Oncol. 1992;20(1):42–47. [PubMed]
  • Craft A, Cotterill S, Malcolm A, Spooner D, Grimer R, Souhami R, Imeson J, Lewis I. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol. 1998 Nov;16(11):3628–3633. [PubMed]
  • Davies SM, Pearson AD, Craft AW. Toxicity of high-dose ifosfamide in children. Cancer Chemother Pharmacol. 1989;24 (Suppl 1):S8–10. [PubMed]
  • De Schepper J, Stevens G, Verboven M, Baeta C, Otten J. Ifosfamide-induced Fanconi's syndrome with growth failure in a 2-year-old child. Am J Pediatr Hematol Oncol. 1991 Spring;13(1):39–41. [PubMed]
  • De Schepper J, Hachimi-Idrissi S, Verboven M, Piepsz A, Otten J. Renal function abnormalities after ifosfamide treatment in children. Acta Paediatr. 1993 Apr;82(4):373–376. [PubMed]
  • Deméocq F, Oberlin O, Benz-Lemoine E, Boilletot A, Gentet JC, Zucker JM, Behar C, Poutard P, Olive D, Brunat-Mentigny M, et al. Initial chemotherapy including ifosfamide in the management of Ewing's sarcoma: preliminary results. A protocol of the French Pediatric Oncology Society (SFOP). Cancer Chemother Pharmacol. 1989;24 (Suppl 1):S45–S47. [PubMed]
  • Devalck C, Ismaili K, Ferster A, Sariban E. Acute ifosfamide-induced proximal tubular toxic reaction. J Pediatr. 1991 Feb;118(2):325–326. [PubMed]
  • Elises JS, Griffiths PD, Hocking MD, Taylor CM, White RH. Simplified quantification of urinary protein excretion in children. Clin Nephrol. 1988 Oct;30(4):225–229. [PubMed]
  • Gasparini M. High-dose ifosfamide alone and in combination for solid malignancies in childhood. Cancer Chemother Pharmacol. 1986;18 (Suppl 2):S18–S18. [PubMed]
  • Hawkins MM, Stevens MC. The long-term survivors. Br Med Bull. 1996 Oct;52(4):898–923. [PubMed]
  • Heney D, Lewis IJ, Bailey CC. Acute ifosfamide-induced tubular toxicity. Lancet. 1989 Jul 8;2(8654):103–104. [PubMed]
  • Holoye PY, Anderson T, Duelge J, Hansen RM, Ritch PS. Use and safety of high-dose ifosfamide. Semin Oncol. 1982 Dec;9(4 Suppl 1):78–86. [PubMed]
  • Kellie SJ, De Kraker J, Lilleyman JS, Bowman A, Pritchard J. Ifosfamide in previously untreated disseminated neuroblastoma. Results of Study 3A of the European Neuroblastoma Study Group. Eur J Cancer Clin Oncol. 1988 May;24(5):903–908. [PubMed]
  • Moncrieff M, Foot A. Fanconi syndrome after ifosfamide. Cancer Chemother Pharmacol. 1989;23(2):121–122. [PubMed]
  • Prasad VK, Lewis IJ, Aparicio SR, Heney D, Hale JP, Bailey CC, Kinsey SE. Progressive glomerular toxicity of ifosfamide in children. Med Pediatr Oncol. 1996 Sep;27(3):149–155. [PubMed]
  • Pratt CB, Douglass EC, Etcubanas EL, Goren MP, Green AA, Hayes FA, Horowitz ME, Meyer WH, Thompson EI, Wilimas JA. Ifosfamide in pediatric malignant solid tumors. Cancer Chemother Pharmacol. 1989;24 (Suppl 1):S24–S27. [PubMed]
  • Pratt CB, Meyer WH, Jenkins JJ, Avery L, McKay CP, Wyatt RJ, Hancock ML. Ifosfamide, Fanconi's syndrome, and rickets. J Clin Oncol. 1991 Aug;9(8):1495–1499. [PubMed]
  • Raney B, Ensign LG, Foreman J, Khan F, Newton W, Ortega J, Ragab A, Wharam M, Wiener E, Maurer H. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. Am J Pediatr Hematol Oncol. 1994 Nov;16(4):286–295. [PubMed]
  • Rossi R, Gödde A, Kleinebrand A, Riepenhausen M, Boos J, Ritter J, Jürgens H. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol. 1994 Jan;12(1):159–165. [PubMed]
  • Sangster G, Kaye SB, Calman KC, Dalton JF. Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity. Eur J Cancer Clin Oncol. 1984 Mar;20(3):435–436. [PubMed]
  • Shaw PJ, Eden T. Ifosfamide in paediatric oncology: tried but not tested? Lancet. 1990 Apr 28;335(8696):1022–1023. [PubMed]
  • Shore R, Greenberg M, Geary D, Koren G. Iphosphamide-induced nephrotoxicity in children. Pediatr Nephrol. 1992 Mar;6(2):162–165. [PubMed]
  • Skinner R, Pearson AD, Price L, Coulthard MG, Craft AW. Nephrotoxicity after ifosfamide. Arch Dis Child. 1990 Jul;65(7):732–738. [PMC free article] [PubMed]
  • Skinner R, Pearson AD, Coulthard MG, Skillen AW, Hodson AW, Goldfinch ME, Gibb I, Craft AW. Assessment of chemotherapy-associated nephrotoxicity in children with cancer. Cancer Chemother Pharmacol. 1991;28(2):81–92. [PubMed]
  • Skinner R, Sharkey IM, Pearson AD, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol. 1993 Jan;11(1):173–190. [PubMed]
  • Skinner R, Pearson AD, English MW, Price L, Wyllie RA, Coulthard MG, Craft AW. Risk factors for ifosfamide nephrotoxicity in children. Lancet. 1996 Aug 31;348(9027):578–580. [PubMed]
  • Smeitink J, Verreussel M, Schröder C, Lippens R. Nephrotoxicity associated with ifosfamide. Eur J Pediatr. 1988 Nov;148(2):164–166. [PubMed]
  • Suarez A, McDowell H, Niaudet P, Comoy E, Flamant F. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report. J Clin Oncol. 1991 Dec;9(12):2177–2182. [PubMed]
  • Van Gool S, Brock P, Wijndaele G, Van de Casseye W, Kruger M, Proesmans W, Casteels-Van Daele M. Reversible hypophosphatemic rickets following ifosfamide treatment. Med Pediatr Oncol. 1992;20(3):254–257. [PubMed]
  • Wheeler BM, Loehrer PJ, Williams SD, Einhorn LH. Ifosfamide in refractory male germ cell tumors. J Clin Oncol. 1986 Jan;4(1):28–34. [PubMed]
  • Zalupski M, Baker LH. Ifosfamide. J Natl Cancer Inst. 1988 Jun 15;80(8):556–566. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK